• The association of body weight and patient-important outcomes remains unknown.
Essentials
• The association of body weight and patient-important outcomes remains unknown.
• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were searched.
• Risk of outcomes varying among body weight subgroups is not attributable to anticoagulant type.
• Dose adjustment of DOACs, outside that recommended, is unlikely to improve the outcomes.
Click to hear Dr Braunwald's perspective on antithrombotic therapy in cardiovascular disease
Summary. Background: Concerns have arisen in direct oral anticoagulant (DOAC)-treated patients about safety and efficacy in extremes of body weight. The aims of this systematic review were to investigate the association of body weight and patient-important outcomes in patients treated with DOACs or warfarin, and to demonstrate the fixed-dose effect of DOACs. Methods: MEDLINE and EMBASE were searched until November 2016. Phase III randomized controlled trials (RCTs) using DOACs in atrial fibrillation (AF) and acute venous thromboembolism (VTE) were included. Relative risk and 95% confidence interval were calculated. The pooled estimates were performed using a Mantel-Haenszel random effects model. Results: A total of 11 phase III RCTs were included. Low body weight was associated with increased risk of thromboembolism compared with non-low body weight (relative risk [RR], 1.57; 95% confidence interval [CI], 1.34-1.85). High body weight was not associated with risk of thromboembolism compared with non-high body weight (RR, 0.88; 95% CI, 0.63-1.23). The subgroup of AF patients with high body weight had a lower risk of thromboembolism compared with non-high body weight (RR, 0.43; 95% CI, 0.28-0.67). Bleeding outcomes were comparable for all body weight comparisons. There were no clear interactions between types of anticoagulant in all outcomes. Conclusion: The pooled effect of both the DOAC and comparison arms was likely to be attributable to differences in baseline thrombotic risk in each body weight category, rather than an effect of the type or dose of DOAC used for each indication. Dose adjustment of DOACs, outside that recommended in the package insert, is unlikely to improve safety or efficacy.
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Background
Direct oral anticoagulants (DOACs) and warfarin are widely used for the prevention of systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE). As DOACs are given in fixed doses without regard to body weight, concerns have arisen about the safety and efficacy of DOACs in patients at the extremes of weight, specifically those with extremely high or low body weight. Clinicians may hesitate to initiate DOACs in these patients because of a perception that the fixed dose might not be sufficiently effective in the high body weight individuals or might increase the bleeding risk in low body weight individuals. Although there are pharmacokinetic studies [1] [2] [3] [4] that have documented drug exposure when DOACs are given to extremely high or low body weight patients, a study that documents the rate of patientimportant outcomes in this population is lacking. A previous meta-analysis of this subject performed such analyses separately for each body weight category and demonstrated comparable efficacy and safety of DOACs for acute VTE compared with warfarin [5] . In our study, we used a different approach to explore the association of extreme body weight relative to normal body weight with thromboembolic and bleeding outcomes in patients treated with DOACs and warfarin for AF and acute VTE, and to demonstrate the fixed dose effect of DOACs. We hypothesized that if the fixed dose effect does not hold true, patients with higher body weight would have a higher rate of thrombosis compared with those with non-high body weight while taking DOACs, but not while taking warfarin (because of international normalized ratio (INR)-driven dosing adjustment). Similarly, low body weight patients would have a higher risk of bleeding compared with nonlow body weight patients while taking DOACs, but not while taking warfarin.
Methods

Data source and search strategy
This systematic review and meta-analysis was conducted and reported according to the PRISMA statement [6] . A literature search was performed via the Ovid platform through PubMed, MEDLINE (1946 to present) and EMBASE (1996 to present). The Cochrane Central Register of Controlled Trials (CENTRAL) and www.Clinica lTrial.gov were searched for unpublished or ongoing registered trials. The US Food and Drug Administration (FDA) reviews of new drug applications and a pharmaceutical industry trial registry (Boehringer Ingelheim, Bristol-Myers Squibb, Bayer and Daiichi Sankyo) were searched for grey literature and unpublished studies. Conference proceedings or abstracts that had been identified from the databases were assessed for eligibility. In addition, we searched online abstracts and conference proceedings (from January 2008 to January 2016) from the congresses of the American Society of Hematology, International Society of Thrombosis and Hemostasis, American College of Cardiology and American Heart Association. Lists of references of potentially relevant articles were manually reviewed and screened for eligibility. For MEDLINE and EMBASE, search terms included: dabigatran, rivaroxaban, apixaban, edoxaban, direct oral anticoagulant*, target-specific oral anticoagulant*, novel oral anticoagulant*, non-vitamin K oral anticoagulant*, DOAC*, NOAC*, TSOAC*, AF, atrial flutter, venous thrombosis, venous thromboembolism, deep vein thrombosis, pulmonary embolism, and clinical trials. All terms were searched by index (subject heading and explosion) and keywords using the OVID platform (Fig. S1) . We limited the search to RCTs comparing the effect of therapy using filter terms recommended by the Health Information Research Unit, McMaster University, which have a sensitivity of 99% [7, 8] . The search was limited to humans. There were no language restrictions. The search was performed on 21 February 2016. Additional searches on MEDLINE and EMBASE were performed on 20 November 2016 to update the results of the analysis.
Study selection
The studies were eligible if they were subgroups of phase III RCTs investigating DOACs, including dabigatran, rivaroxaban, apixaban and edoxaban, for the prevention of stroke and systemic embolism in AF and in acute VTE treatment, or sub-studies or subgroup analysis of the phase III RCTs. All included studies reported thromboembolic or bleeding outcomes by body weight or body mass index (BMI). Low body weight was defined by the investigators in each study but had to be less than or equal to 60 kg. High body weight was similarly defined for each study but was a minimum of 100 kg. Normal body weight was defined as being between the cut-offs of high and low body weight in each study. Obesity was defined as a BMI of more than 30 kg m
À2
. Studies examining DOACs for primary prevention of VTE in orthopedic surgery and medically ill patients, extended treatment of VTE or other indications (acute coronary syndrome, atrial thrombus, perioperative management and antiphospholipid syndrome) were excluded.
Two reviewers (K.B. and F.C) independently screened titles and abstracts of the retrieved studies using predefined inclusion and exclusion criteria. After a calibration exercise, we developed additional inclusion criteria to improve agreement.
Full text eligibility, including the supplementary indexes, of the studies was assessed independently by two reviewers (K.B. and F.C.). For highly relevant conference proceedings or abstracts, we contacted the authors for additional information. Disagreement was resolved by discussion. If this disagreement could not be resolved, a third adjudicator (C.C.-A.) was contacted to make a final decision. The Kappa statistic was calculated to determine the inter-rater agreement between two reviewers.
Data abstraction and quality assessment
Two reviewers (K.B. and F.C.) independently abstracted data using a study-specific data extraction sheet.
Thromboembolic outcomes including stroke and/or systemic embolism in AF studies and symptomatic recurrent VTE or VTE-related death in VTE studies were recorded by subgroups of body weight or BMI as provided by the studies. Bleeding outcomes, including major bleeding as defined by the International Society on Thrombosis and Hemostasis (ISTH) [9] and/or clinically relevant non-major bleeding (CRNMB), were recorded for each subgroup of body weight or BMI as provided by the studies. For studies that reported the outcome only as a rate (%/year), the rate was converted to the number of events assuming a constant risk during the follow-up period.
The risk of bias was assessed using the modified Newcastle-Ottawa scale. This was appropriate because we treated a single arm derived from RCTs as a prospective observational study [10] . This scale evaluates the risk of bias in the selection of the study population, confidence in exposures, comparability of the cohorts, the adequacy of follow-up and outcome assessment. It has an additional assessment of prognostic factors and impact of cointervention on the study conclusions. The overall risk of bias for each outcome was assessed by two independent reviewers (K.B. and F.C.). Publication bias was not formally assessed by a funnel plot because of the small number of included studies. The quality of evidence of each outcome was assessed using the Grading of Recommendation Assessment Development and Evaluation score [11] by two independent reviewers (K.B. and F.C.).
Statistical analysis
Study characteristics were summarized. The effect measures for each study were calculated and reported as a relative risk (RR) with 95% confidence intervals (CIs).
Meta-analysis was performed using a random effects model and the effect measures of the included studies were pooled using a Mantel-Haenzel method. A random effects model was used based on the assumption that there was heterogeneity in the individual studies because of variation in types of anticoagulants, indication for treatment, DOAC type and duration of treatment. We performed meta-analyses separately for the DOAC and warfarin arms. When no significant difference in the effect estimate between groups was observed, we pooled the data from the DOACs and warfarin arms together to increase the power of the analysis. The results of the separate analyses are presented in the supplementary material (Fig. S7) . The metaanalyses were performed using Review Manager 5.3 software. Heterogeneity was explored based on a priori hypotheses using visual inspection and the Cochrane Q test. A P-value < 0.05 was considered statistically significant. The I 2 statistic was calculated to provide a quantitative estimate of heterogeneity.
Subgroup analysis
We specified four a priori hypotheses, including type of anticoagulant (DOACs vs. warfarin), indication (AF vs. VTE), type of DOAC (direct thrombin inhibitor vs. factor Xa inhibitor) and studies with low or standard doses of DOACs. During data abstraction, we found that four studies had adjusted DOAC dose in patients with low body weight or those with impaired renal function (creatinine clearance 30-50 mL min À1 ), age > 80 years or concomitant use of potent P-glycoprotein inhibitors. Thus, an additional post-hoc subgroup analysis of the DOAC studies with dose adjustment vs. studies without dose adjustment was performed. If there was only one study in one of the subgroups, the analysis was not performed.
Sensitivity analysis Five sensitivity analyses were performed: (i) exclusion of studies that adjusted DOAC dose according to body weight, (ii) comparison of high vs. normal body weight instead of high vs. non-high body weight, (iii) comparison of low vs. normal body weight instead of low vs. non-low body weight (excluded data from ARISTOTLE and ENGAGE TIMI-48 because we were unable to define a normal body weight group), (iv) comparison of BMI > 35 kg m À2 and < 30 kg m À2, and (v) performing the analyses on the thromboembolic and bleeding outcomes for the studies with a similar body weight cut-off.
Results
We identified 6587 articles through title and abstract screening: 2614 articles from MEDLINE, 3511 articles from EMBASE, 212 from PubMed and 250 articles from other sources; 1058 duplicate articles were excluded. A total of 5169 articles were excluded after title and abstract screening, leaving 360 articles for full text review. A further 336 studies were excluded: 204 articles were abstracts, RCTs or sub-studies of RCTs that did not report outcomes by subgroups of body weight or BMI, 110 articles were not RCTs, 10 articles examined an ineligible population and 12 articles were duplicates. Twentyfour articles remained for data abstraction. These included 12 RCTs, three FDA briefing documents, three highly relevant abstracts and six sub-studies of RCTs. We received more information from the authors of two abstracts. During data abstraction, eight articles were excluded: five sub-studies of RCTs, one abstract with less informative data, one RCT and one sub-study of an RCT with insufficient information (Fig. S2 ). The unweighted Kappa statistics for full text eligibility between the two reviewers was 0.89 (95% CI, 0.88-0.99).
Study characteristics
A total of 11 RCTs were included. Characteristics of the included studies are shown in Table 1 . Two pairs of RCTs [12] [13] [14] [15] were reported as pooled studies; thus they were treated as two unique studies (RECOVERI, II and EIN-STEIN DVT, PE) [12, 16] . Four studies adjusted the dose of DOACs in patients with low body weight under selected circumstances (ARISTOTLE, ENGAGE-TIMI-48, Hokusai study and AVERROES). One of the nine studies did not report thromboembolic outcomes by subgroups of body weight [17] . Two of the nine studies did not report bleeding outcome by subgroups of body weight [12, 17] . Three studies did not report thromboembolic outcome by subgroups of BMI [17] [18] [19] and three studies did not report bleeding outcome by subgroups of BMI [12, 18, 19] . The low body weight cut-off level was 60 kg in four studies and 50 kg in four studies. The high body weight cut-off was 100 kg in five studies and 110 kg in one study. Two studies did not have a high body weight cut-off and thus were not included in the high body weight comparison (ARISTO-TLE and ENGAGE-TIMI-48). [17, 19] .
Risk of bias assessment
The assessment of risk of bias using the modified NewcastleOttawa scale is summarized in the supplementary material (Table S1 ). The quality of evidence assessed by GRADE was very low for all outcomes. Because our analysis used single arms derived from RCTs as observational studies, the quality of evidence began at low quality, and the quality was downgraded because of lack of baseline adjustment and indirectness.
Outcomes
Low body weight vs. non-low body weight patients Thromboembolic outcomes Eight studies with a total of 98 244 patients were included in the meta-analysis [12] [13] [14] [15] [16] [19] [20] [21] [22] [23] [24] . Thromboembolic events occurred in 278 of 6497 patients (4.28%) in the low body weight and in 2513 of 91 747 patients (2.74%) in the non-low body weight groups (RR, 1.57; 95% CI, 1.34-1.85; P < 0.0001; I 2 = 29% [Fig. 1] ; absolute difference in risk [low body weight minus non-low body weight], 0.01; 95% CI, 0.0057-0.0187; P = 0.0002). Subgroup analyses based on type of anticoagulant, indication, and type and dose of DOACs and studies with dose adjustment were performed and provided similar results to the primary analysis (Fig. S3) .
Bleeding outcomes Seven studies with a total of 95 223 patients were included in the meta-analysis [13] [14] [15] [16] [19] [20] [21] [22] [23] [24] . Bleeding outcomes occurred in 502 of 8420 patients (5.96%) in the low body weight group and in 5280 of 86 803 patients (6.08%) in the non-low body weight group (RR, 0.97; 95% CI, 0.86-1.10; P = 0.67; I 2 = 41%) (Fig. 2) . Subgroup analyses based on type of anticoagulant (Fig. 3) , indication and dose of DOAC and studies with dose adjustment provided similar results to the primary analysis (Fig. S3) .
High body weight and non-high body weight patients Thromboembolic outcomes Six studies with a total of 59 079 patients were included in the meta-analysis [12] [13] [14] [15] [16] [20] [21] [22] [23] . Thromboembolic outcomes occurred in 196 of 8623 patients (2.27%) in the high body weight group and in 1453 of 50456 patients (2.88%) in the non-high body weight group (RR, 0.88; 95% CI, 0.63-1.23; P = 0.46; I 2 = 77%) (Fig. 4) . Subgroup analysis based on type of anticoagulant (Fig. 5) and type of DOAC provided similar results to the primary analysis (Fig. S4) . Subgroup analysis based on indication demonstrated a significant interaction (P for interaction < 0.0001). The risk of thromboembolism was lower in high body weight patients compared with non-high body weight patients in AF patients (RR, 0.43; 95% CI, 0.28 to 0.67; P = 0.0002), but not in VTE patients (RR, 1.23; 95% CI, 1.00-1.53; P = 0.05) (Fig. 6) . Subgroup credibility was assessed using criteria proposed by Sun et al. [25] (Table S2 ). The credibility of the subgroup effect was plausible.
Bleeding outcomes Five studies with a total of 54 165 patients were included in the meta-analysis [14] [15] [16] [20] [21] [22] [23] . Bleeding outcomes occurred in 511 of 7810 patients (6.54%) in the high body weight group and in 3179 of 46 355 patients (6.86%) in the non-high body weight group (RR, 0.93; 95% CI, 0.82-1.06; P = 0.31; I 2 = 43) (Fig. 7) . Subgroup analyses based on type of anticoagulant and indication provided similar results to the primary analysis (Fig. S4 ).
Obesity and non-obesity Thromboembolic outcomes Six studies with a total of 68 870 patients were included in the meta-analysis [12, [14] [15] [16] 20, 21, 24] . Thromboembolic outcomes occurred in 564 of 24 594 obese patients (2.29%) and in 1286 of 44 276 non-obese patients (2.90%) (RR, 0.81; 95% CI, 0.71-0.93; P = 0.002; I 2 = 39%; absolute difference in risk [obesity minus nonobesity], À0.0055; 95% CI, À0.0088 to À0.0022; P = 0.001). Subgroup analyses based on type of anticoagulant and type of DOAC provided similar results to the primary analysis. Subgroup analyses based on indication demonstrated a significant interaction (P = 0.03). The risk of thromboembolism was lower in obese compared with non-obese patients with AF (RR, 0.73; 95% CI, 0.65 to 0.82; P < 0.001) but not in VTE patients (RR, 1.02; 95% CI 0.78-1.33; P = 0.13) (Fig. S5) .
Bleeding outcomes Six studies with a total of 66 697 patients were included in the meta-analysis [14] [15] [16] [17] 20, 21, 23, 24] . The aspirin arm of the AVERROES study was not included in the analysis. Bleeding outcomes occurred in 2487 of 41 672 obese patients (5.97%) and in 1344 of 25 025 non-obese patients (5.37%) (RR, 1.06; 95% CI, 0.99 to 1.14; P = 0.12; I 2 =17%). Subgroup analyses based on type of anticoagulant and indication provided similar results to the primary analysis.
Sensitivity analysis
Five sensitivity analyses were performed as defined previously. In all cases the analysis supported the results of the primary analyses (Fig. S6 ).
Discussion
Our systemic review explores the association between body weight and thromboembolic or bleeding outcomes in DOAC and warfarin-treated patients across a range of body weights and indications. The results of our systematic review do not support our hypothesis that patients with high body weight would have a higher rate of thrombosis or low body weight patients would have a higher risk of bleeding while taking DOACs, but not while taking warfarin. We found that low body weight patients treated with DOACs and with warfarin have an increased risk of thromboembolism but no increase in bleeding risk compared with that in non-low body weight patients, reported in both VTE and AF patients [26] [27] [28] . Several factors could explain this observation. Low body weight could be a consequence of chronic illness such as malignancy, which is also associated with an increased risk of venous thrombosis. We also observed that heavier patients have a favorable thromboembolic outcome. This observation, the so-called 'obesity paradox', has been reported in patients with AF, congestive heart failure, coronary heart disease and end-stage kidney disease. [29] [30] [31] [32] . A post-hoc analysis of the ARISTOTLE trial demonstrated a significant risk reduction in all-cause mortality and the composite endpoint of stroke and systemic embolism, myocardial infarction and death in obese compared with non-obese patients [33] . There is no clear explanation for this observation; perhaps higher body weight patients might receive optimal cardiovascular medications more often than non-high body weight patients, resulting in a lower risk of thromboembolic and cardiovascular outcomes [33, 34] . In our study, low body weight patients treated with DOACs had no difference in bleeding compared with non-low body weight patients. Likewise, high body weight and obese patients had no difference in bleeding risk compared with non-high body weight or non-obese patients. Subgroup analysis of bleeding outcomes did not demonstrate a significant interaction between studies with dose adjustment and those with no dose adjustment. The results were confirmed in a sensitivity analysis where we excluded patients who had their DOAC dose adjusted based on body weight or other characteristics. If one follows approved prescribing information, these findings support that decreasing doses in individuals with lower weight may not be required.
The modest changes in dabigatran, rivaroxaban and apixaban exposure seen in early pharmacokinetic studies suggest that it is unlikely to require dose adjustment according to body weight [1] [2] [3] [4] . In a phase II RCT of edoxaban in AF patients, body weight less than 60 kg was an independent risk factor for major bleeding in the edoxaban 60 mg group compared with the warfarin group. [35] Thus, in subsequent RCTs, the doses of edoxaban were reduced by 50% if patients had any of these three criteria: body weight less than 60 kg, impaired renal function or concomitant use of potent P-glycoprotein inhibitors. Our study supports the previous PK studies of DOACs [1] [2] [3] 35] showing that body weight has only a modest effect on the pharmacokinetic profile of DOACs as we did not observe a higher rate of thromboembolism in high body weight patients or a higher rate of bleeding in low body weight patients.
As our study included different types of DOACs, the results require cautious interpretation. In the dabigatran VTE studies [12, 13] heavier patients treated with either dabigatran or warfarin had a significant increase in their Pool EINSTEIN DVT-PE-D, 2015 Pool EINSTEIN DVT-PE-W, 2015 Hokusai-W, 2013 Hokusai The ENGAGE TIMI-48 and ARISTOTLE studies were not included in the analysis because they did not specify high body weight categories, as were the AVERROES and RECOVER studies because they did not report bleeding outcomes according to body weight. [Color figure can be viewed at wileyonlinelibrary.com] less than 60 kg, impaired renal function or concomitant use of potent P-glycoprotein inhibitors.
Although none of the included RCTs had an upper weight limit in their inclusion criteria, three studies have reported the proportion of extremely high body weight patients (body weight > 120 kg or BMI > 40 kg m À2 ) participating in the study. In a post-hoc analysis of the pooled EINSTEIN studies, 222 of 8271 patients (3.67%) had body weight between 120 and 140 kg and 81 of 8271 (1%) had body weight greater than 140 kg [16] . In a posthoc analysis from the ARISTOTLE study, 1006 of 18 107 patients (5.55%) had BMI > 40 kg m À2 [36] . As only a few studies reported outcomes in extremely high body weight patients, we could not perform a separate analysis in this population. To our knowledge, there are no published systematic reviews and/or meta-analyses specifically investigating the association of outcomes across a broad range of weights in DOAC and warfarin-treated patients. Strengths of this systematic review include the large number of patients, including more than 90 000 patients across the two largest indications for DOAC use. Second, all included studies were large well-conducted RCTs. Last, the body weight threshold used in each study was representative of the low body weight and high body weight populations.
Our study has limitations. First, owing to the studylevel meta-analysis of subgroups, we were unable to adjust for baseline characteristics between body weight subgroups. This could be further addressed by metaregression or an individual patient-level meta-analysis. Second, the associations we observed do not demonstrate causation and should not be interpreted as such. Third, although low body weight patients were well represented, very few extremely high body weight patients were included; thus our findings do not apply to extremely high body weight patients (e.g. those weighing more than 120 kg). Fourth, body weight was measured at baseline for all studies; thus we did not account for the change in body weight during the study. Fifth, the results of our study can only be applied with caution to those DOACs that used dose adjustment per body weight in their constituent trials. Sixth, inconsistent reporting on body weight or BMI for each outcome between studies resulted in a varying number of studies included in the meta-analyses for each outcome. Finally, we observed a heterogeneity in thromboembolic outcome in the high body weight comparison. However, we explored the heterogeneity based on a priori hypotheses and found that the subgroup effect was significant. In addition, subgroup credibility was assessed and the effect was plausible.
In conclusion, in AF and VTE patients treated with DOACs or with warfarin, we found that patients with low body weight had a paradoxical increase in the risk of thromboembolism compared with non-low body weight patients. The subgroup of AF patients with a high body weight had a favorable thromboembolic outcome compared with AF patients with a non-high body weight. These differences in thrombosis risk according to body weight were seen in both the DOAC and the comparison arms and were likely to be attributable to differences in other patient characteristics known to affect the baseline risk of thromboembolism, rather than the type of anticoagulant. We conclude that dose adjustment of DOACs, outside that recommended in the package insert, is unlikely to improve safety or efficacy. 
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